Across every specialty in medicine, there is an emphasis on collaborative care and holistic management. Although collaborative care is not novel in management of cardiovascular disease, it has undertaken new meaning in recent years due to the revelations of the benefits surrounding antihyperglycemic agents.
This has led to unprecedented levels of collaboration between the fields of endocrinology, cardiology, and nephrology. The last decade has been a whirlwind of major clinical trials shedding light on the benefits of these agents for cardiovascular- and renal-related outcomes—first, in those with diabetes and, next, in populations without diabetes.
The effects of this collaboration were on full display the American Heart Association 2022 Scientific Sessions, which featured a presentation on the results of the landmark EMPA-KIDNEY trial and a multitude of sessions and presentations dedicated to cardiometabolic health. In one particular session, which featured more than a dozen experts across the fields of diabetes management, cardiology, and nephrology, a pair of expert panels examined case reports and discussed how various cardiometabolic health guidelines from different organizations can be interpreted and applied to patient populations.
Among the panelists included in the session was Diana Isaacs, PharmD, continuous glucose monitoring coordinator and endocrine clinical pharmacist at the Cleveland Clinic. A Certified Diabetes Care and Education Specialist, Isaacs touts a unique perspective on management of cardiometabolic health with newer agents as she holds board certifications in pharmacotherapy, ambulatory care, and advanced diabetes management. To learn more about the collaboration occurring within the emerging field of cardiometabolic health, our editorial team sat down for an interview with Isaacs following the aforementioned session at AHA 22 and that interview is the subject of the video found below.